Primary and secondary prevention in obesity

International Journal of Clinical Practice

Volumn 61, Issue 9, 2007, Pages 1431-1434

  Wierzbicki, Anthony S ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLITAZONE DERIVATIVE; INSULIN; MEGLITINIDE; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PRAMLINTIDE; RAMIPRIL; RIMONABANT; ROSIGLITAZONE; SIBUTRAMINE; SITAGLIPTIN; SULFONYLUREA; TETRAHYDROLIPSTATIN; TROGLITAZONE; UNCLASSIFIED DRUG; VIDAGLIPTIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIET THERAPY; DRUG COST; DRUG EFFICACY; EDITORIAL; GLYCEMIC CONTROL; HIGH RISK BEHAVIOR; HUMAN; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIVER FAILURE; METABOLIC DISORDER; OBESITY; PRIORITY JOURNAL; RISK FACTOR; SMOKING;

BODY MASS INDEX; CORONARY ARTERIOSCLEROSIS; HUMANS; OBESITY;

EID: 34547819209     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01499.x     Document Type: Editorial

References (34)

1. National Heart Lung & Blood Institute. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda, MD : National Institutes of Health, 2000. Report no.: Publ. no. 00-4084.
2. Yusuf S, Ounpuu S, Anand S. The global epidemic of atherosclerotic cardiovascular disease. Med Princ Pract 2002 11 (Suppl. 2 3 8.
3. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001 414 : 782 7.
4. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 346 : 393 403.
5. Lindstrom J, Louheranta A, Mannelin M et al. The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003 26 : 3230 6.
6. Sattar N, Gaw A, Scherbakova O et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003 108 : 414 9.
7. Hanley AJ, Karter AJ, Williams K et al. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation 2005 112 : 3713 21.
8. Wilson PW, Meigs JB, Sullivan L et al. Prediction of incident diabetes mellitus in middle-aged adults: The Framingham Offspring Study. Arch Intern Med 2007 167 : 1068 74.
9. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 53.
10. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998 352 : 854 65.
11. Cheng AY, Fantus IG. Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ 2005 172 : 213 26.
12. Uwaifo GI, Ratner RE. Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk. Am J Cardiol 2007 99 : 51B 67B.
13. Rodgers PT, Fuke DC. New and emerging strategies for reducing cardiometabolic risk factors. Pharmacotherapy 2006 26 (5 Pt 2 13S 31S.
14. Buse JB, Tan MH, Prince MJ et al. The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab 2004 6 : 133 56.
15. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006 355 : 2427 43.
16. Gerstein HC, Yusuf S, Bosch J et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006 368 : 1096 105.
17. Stumvoll M, Haring HU. Glitazones: clinical effects and molecular mechanisms. Ann Med 2002 34 : 217 24.
18. Knowler WC, Hamman RF, Edelstein SL et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005 54 : 1150 6.
19. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007 356 : 2457 7.
20. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005 366 : 1279 89.
21. Yki-Jarvinen H. The PROactive study: some answers, many questions. Lancet 2005 366 : 1241 2.
22. Ahren B. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes Care 2007 30 : 1344 50.
23. Gallwitz B. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data. Int J Clin Pract 2006 60 : 1654 61.
24. Lean M, Mullan A. Obesity: which drug and when Int J Clin Pract 2007 61 : 1555 60.
25. Van Gaal LF, Wauters MA, De L. I. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes Relat Metab Disord 1997 21 (Suppl. 1 S5 S9.
26. Wierzbicki AS. Rimonabant: endocannabinoid inhibition for the metabolic syndrome. Int J Clin Pract 2006 60 : 1697 706.
27. Metz JA, Stern JS, Kris-Etherton P et al. A randomized trial of improved weight loss with a prepared meal plan in overweight and obese patients: impact on cardiovascular risk reduction. Arch Intern Med 2000 160 : 2150 8.
28. Torgerson JS, Hauptman J, Boldrin MN et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004 27 : 155 61.
29. Kelley DE, Jneidi M. Orlistat in the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother 2002 3 : 599 605.
30. Fujioka K, Seaton TB, Rowe E et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2000 2 : 175 87.
31. Scheen AJ, Van Gaal LF. [Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes]. Rev Med Liege 2007 62 : 81 5.
32. Wierzbicki AS. Low HDL-cholesterol: common and under-treated, but which drug to use Int J Clin Pract 2006 60 : 1149 53.
33. Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003 348 : 383 93.
34. Sjostrom L, Lindroos AK, Peltonen M et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004 351 : 2683 93.